Saturday, 31 October 2026European Markets

GPE GROUP PIZZORNO Stock Over 28% Up In The Last 21 Sessions

Loading stream...

(vianews) - shares of gpe group pizzorno (cac 40: gpe.pa) rose by a staggering 28.21% in 21 sessions from €42.9 to €55.00 at 17:52 est on wednesday, following the last session's downward trend. cac 40 is sliding 1.7% to €7,087.30, after two successive sessions in a row of losses.

about gpe group pizzorno

groupe pizzorno environnement provides environmental services primarily in france. it engages in the production and recycling of secondary raw materials; development of technologies and services for the recovery of bio-waste; production of heat and electricity from waste treatment; and processing and collection of household waste, as well as offers cleanliness services. groupe pizzorno environnement was founded in 1974 and is headquartered in draguignan, france.

earnings per share

as for profitability, gpe group pizzorno has a trailing twelve months eps of €4.89.

pe ratio

gpe group pizzorno has a trailing twelve months price to earnings ratio of 11.25. meaning, the purchaser of the share is investing €11.25 for every euro of annual earnings.

volume

today's last reported volume for gpe group pizzorno is 528 which is 10.2% above its average volume of 441.

more news about gpe group pizzorno (gpe.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,514 source documents archived
Query this data → isubstrate.com